Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.
Int J Infect Dis
; 146: 107160, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-38969330
ABSTRACT
OBJECTIVES:
This study evaluated relative vaccine effectiveness (rVE) of MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV) vs high-dose trivalent inactivated influenza vaccine (HD-TIV) for prevention of test-confirmed influenza emergency department visits and/or inpatient admissions ("ED/IP") and for IP admissions alone pooled across the 2017-2020 influenza seasons. Exploratory individual season analyses were also performed.METHODS:
This retrospective test-negative design study included United States (US) adults age ≥65 years vaccinated with aTIV or HD-TIV who presented to an ED or IP setting with acute respiratory or febrile illness during the 2017-2020 influenza seasons. Test-positive cases and test-negative controls were grouped by vaccine received. The rVE of aTIV vs HD-TIV was evaluated using a combination of inverse probability of treatment weighting and logistic regression to adjust for potential confounders.RESULTS:
Pooled analyses over the three seasons found no significant differences in the rVE of aTIV vs HD-TIV for prevention of test-confirmed influenza ED/IP (-2.5% [-19.6, 12.2]) visits and admissions or IP admissions alone (-1.6% [-22.5, 15.7]). The exploratory individual season analyses also showed no significant differences.CONCLUSIONS:
Evidence from the 2017-2020 influenza seasons indicates aTIV and HD-TIV are comparable for prevention of test-confirmed influenza ED/IP visits in US adults age ≥65 years.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Polissorbatos
/
Estações do Ano
/
Esqualeno
/
Vacinas contra Influenza
/
Adjuvantes Imunológicos
/
Influenza Humana
/
Eficácia de Vacinas
/
Hospitalização
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article